Razorfish: Mayer De...
Health Care: Drugs
Advanced Cell Tech Inc. (ACTC: OTC)
$0.07 0.00 | -5.62%
05/20/13 - 03:58 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 7.24M | 13.10M | 15.89M | 2.54M |
| Receivables | 96.42K | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 7.55M | 13.41M | 15.98M | 2.64M |
| Property, Plant & Equipment, Gross | 1.12M | 2.38M | 2.35M | 2.17M |
| Accumulated Depreciation & Depletion | 941.73K | 2.23M | 2.16M | 2.05M |
| Property, Plant & Equipment, Net | 175.26K | 154.77K | 185.10K | 113.90K |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 598.31K | 1.39M | 2.59M | 1.95M |
| Total Non-Current Assets | 943.79K | 1.78M | 3.07M | 2.45M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 8.50M | 15.19M | 19.05M | 5.09M |
| Accounts Payable | 2.96M | 2.13M | 1.98M | 6.17M |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 15.31M |
| Other Current Liabilities | 460.67K | 0.00 | 544.12K | 56.60K |
| Total Current Liabilities | 22.20M | 55.75M | 11.34M | 24.38M |
| Long Term Debt | 3.16M | 383.17K | 1.20K | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 6.87K |
| Other Non-Current Liabilities | 3.39M | 3.75M | 30.09M | 23.95M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 8.15M | 5.56M | 31.36M | 26.80M |
| Total Liabilities | 30.36M | 61.31M | 42.71M | 51.17M |
| Preferred Stock Equity | 3.00 | 2.00 | 1.00 | 0.00 |
| Common Stock Equity | -21.86M | -46.12M | -23.65M | -46.08M |
| Common Par | 2.23M | 1.74M | 1.44M | 663.65K |
| Additional Paid In Capital | 289.84M | 229.32M | 166.03M | 79.83M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -282.31M | -253.81M | -180.95M | -126.58M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | -31.62M | -23.38M | -10.18M | 0.00 |
| Total Capitalization | -18.69M | -45.74M | -23.65M | -46.08M |
| Total Equity | -21.86M | -46.12M | -23.65M | -46.08M |
| Total Liabilities & Stock Equity | 8.50M | 15.19M | 19.05M | 5.09M |
| Total Common Shares Outstanding | 2.23B | 1.74B | 1.44B | 663.65M |
| Preferred Shares | 2.75K | 2.15K | 1.40K | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 2.09B | 1.58B | 1.22B | 521.34M |
| Diluted Weighted Shares Outstanding | 2.09B | 1.58B | 1.22B | 521.34M |
| Number of Employees | 36 | 30 | 22 | 14 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with ACTC
- Portfolio NameUser Type
- UserKJ Stocks
- UserMark
- UserBiotech88
- UserThe Jayden Project
- Userwright stocks
- UserRimp's Stockpicks
- UserMy Portfolio
- User2
- User1
- UserRAPTOR LAST 2
Latest ACTC Headlines from TheStreet
- Thursday's Small-Cap Winners & Losers 06.21.07 | 04:06 pm
Press Releases for ACTC
- Advanced Cell Technology, Cytomedix And Mesoblast To Provide Corporate And Clinical Updates At Regen Med Investor Day - PR Newswire 04.09.13 | 12:04 pm
- ACT’s Chief Scientific Officer Dr. Robert Lanza To Deliver The Nerem Lecture 2013 At The 17th Annual Hilton Head Workshop - Business Wire 03.22.13 | 08:03 am
- Advanced Cell Technology Receives Approval From Data Safety Monitoring Board (DSMB) To Initiate Treatment Of Third Patient Cohort In All Three Clinical Trials - Business Wire 03.14.13 | 08:03 am
- ACT’s Dr. Robert Lanza Voted Top 4 “Most Influential People On Stem Cells” - Business Wire 03.12.13 | 08:03 am
- Advanced Cell Technology To Present At BIO-Europe Spring 2013 - Business Wire 03.08.13 | 12:03 pm
- Advanced Cell Technology Announces Fourth-Quarter And Year-end Results - Business Wire 03.07.13 | 04:03 pm
- Advanced Cell Technology To Announce Fourth Quarter And Year-end Results On Thursday March 7th - Business Wire 03.04.13 | 09:03 am
- ACT’s Chief Scientific Officer Robert Lanza, MD, Appointed Editor-in-Chief Of BioResearch Open Access Journal - Business Wire 02.11.13 | 11:02 am
- ACT’s Clinical Partner Receives FDA Approval To Initiate Clinical Trial Using The Company’s HESC-derived Cells To Treat Severe Myopia - Business Wire 02.11.13 | 08:02 am
- Advanced Cell Technology To Present At 15th Annual BIO CEO & Investor Conference - Business Wire 02.08.13 | 08:02 am
Partner Headlines for ACTC
- First patients picked for stem cell vision trials - Reuters 06.16.11 | 09:06 am
- UPDATE 3-US court backs federal embryonic stem cells funds - Reuters 04.29.11 | 02:04 pm
- FDA OKs second Advanced Cell stem cell trial - Reuters 01.03.11 | 11:01 am
- UPDATE 2-Second US company gets stem cell go-ahead - Reuters 11.22.10 | 02:11 pm
- UPDATE 3-First patient treated in Geron stem cell trial - Reuters 10.11.10 | 03:10 pm
- Geron given FDA go-ahead for stem cells trial - Financial Times 07.30.10 | 06:07 pm
